ASCO 2026: BeOne Medicines presented at this year's meeting long-term data on Brukinsa in CLL and combo data with the company's Bcl-2. Chairman & CEO John V. Oyler discusses that and new modalities
He highlights the importance of the long term Brukinsa data, which is the top selling BTK inhibitor today. Plus, we discuss degraders, antibody-drug conjugates, and bispecifics.










.png)